全球市场规模、份额、成长分析（按类型、按应用）-癌症支持治疗药物产业预测，2023-2030 年

Global Cancer Supportive Care Drugs Market Size, Share, Growth Analysis, By Type(ESA (Erythropoiesis-Stimulating Agents), G-CSFs (Granulocyte Colony-Stimulating Factors)), By Application(Breast Cancer, Lung Cancer) - Industry Forecast 2023-2030

出版日期: 2024年02月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年癌症支持治疗药物的全球市场规模估值为883亿美元，从2023年的942.2亿美元增长到2031年的1582.9亿美元，预计在预测期内（2024-2031年）将增长。年复合增长率为6.70%。

全球癌症支持治疗药物市场正在帮助减轻癌症治疗的副作用并提高癌症患者的整体生活品质。由于化疗、放射线治疗和标靶治疗等治疗方法通常会产生使人衰弱的副作用，因此支持性治疗药物对于症状管理至关重要。由于癌症发病率上升、老年人口增加以及癌症治疗方法的进步等因素，该市场正在显着扩大。支持性治疗药物包括多种药物，例如止吐剂、镇痛剂和造血剂，旨在减少治疗的副作用。持续的研究和开发工作致力于创造更准确、更有效的支持性护理。製药公司正在共同努力提供整合癌症治疗和支持性护理药物的综合治疗方案。癌症治疗方法的进步预计将进一步增加对支持性护理药物的需求。市场成长的主要驱动力包括以患者为中心的方法以及提高对治疗期间维持患者健康重要性的认识。针对治疗相关副作用和改善患者舒适度的治疗方法的持续开发，将在塑造全球癌症支持治疗药物市场的未来发挥至关重要的作用。我认为这会奏效。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东/非洲
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2021年）
主要市场参与者所采取的策略
关键成功策略
近期市集活动
主要企业市场占有率（2021年）

主要企业简介

安进公司（美国）
强生公司（美国）
罗氏控股公司（瑞士）
Amneal Pharmaceuticals LLC（美国）
诺华公司（瑞士）
辉瑞公司（美国）
迈兰 NV（美国）
百时美施贵宝（美国）
默克公司（美国）
易普森製药（法国）
礼来公司（美国）
梯瓦製药工业股份有限公司（以色列）
Helsinn Healthcare SA（瑞士）
葛兰素史克公司（英国）
F. Hoffmann-La Roche Ltd.（瑞士）
武田药品工业株式会社（日本）
卫材株式会社（日本）
安斯泰来製药公司（日本）
萌蒂製药国际股份有限公司（英国）
赛诺菲（法国）
拜耳公司（德国）
阿斯特捷利康公司（英国）
协和麒麟株式会社（日本）
雷迪博士实验室有限公司（印度）
太阳製药工业有限公司（印度）

简介目录

Product Code: SQMIG35I2226

Global Cancer Supportive Care Drugs Market size was valued at USD 88.3 billion in 2022 and is poised to grow from USD 94.22 billion in 2023 to USD 158.29 billion by 2031, growing at a CAGR of 6.70% during the forecast period (2024-2031).

The global market for cancer supportive care drugs is instrumental in alleviating the adverse effects of cancer treatments and improving the overall quality of life for cancer patients. Therapies like chemotherapy, radiation, and targeted treatments often bring about debilitating side effects, making supportive care drugs indispensable for symptom management. This market has experienced substantial expansion driven by factors such as rising cancer prevalence, a growing elderly population, and advancements in cancer therapies. Supportive care drugs encompass a diverse range of pharmaceuticals, including antiemetics, analgesics, hematopoietic agents, among others, aiming to mitigate treatment side effects. Continuous research and development efforts are focused on creating more precise and efficacious supportive care therapies. Pharmaceutical companies are collaborating to offer comprehensive treatment options integrating cancer therapies with supportive care drugs. Anticipated advancements in cancer treatment methods are expected to further drive the demand for supportive care drugs. Key drivers of the market's growth include a patient-centric approach and increased awareness of the importance of maintaining patient well-being during treatment. The ongoing development of innovative therapies targeting treatment-related side effects and enhancing patient comfort will play a pivotal role in shaping the future landscape of the global cancer supportive care drugs market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Supportive Care Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Supportive Care Drugs Market Segmental Analysis

By Type, the market is segmented into ESA (Erythropoiesis-Stimulating Agents), G-CSFs (Granulocyte Colony-Stimulating Factors), Antiemetics, Bisphosphonates, Opioids, NSAIDs (Non-Steroidal Auto Inflammatory Drugs), Others. By Application, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer, Others. By distribution channel, the market is segmented into Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Cancer Supportive Care Drugs Market

The escalating worldwide incidence of cancer underscores the growing necessity for cancer supportive care medications. As more individuals undergo treatments such as chemotherapy, radiation therapy, and targeted therapies, the demand intensifies for managing the adverse effects associated with these interventions. Supportive care drugs play a crucial role in enhancing patients' quality of life by alleviating symptoms such as nausea, pain, anemia, and fatigue, thereby providing significant relief throughout their cancer treatment journey.

Restraints in the Global Cancer Supportive Care Drugs Market

The complex process of approving cancer supportive drugs stems from the necessity for rigorous clinical trials to ascertain their safety and efficacy. This intricate approval procedure, governed by regulatory barriers and stringent development and marketing guidelines, often leads to delays in introducing new medications to the market. Consequently, patients encounter challenges accessing innovative supportive care options, thereby limiting their treatment choices.

Market Trends of the Global Cancer Supportive Care Drugs Market

With the evolving landscape of cancer treatments tailored to individual patients, there's a growing recognition of the importance of personalized supportive care. This approach acknowledges the unique characteristics of each patient's cancer type, treatment regimen, and health status, leading to the development of specialized drugs to mitigate specific side effects and symptoms such as chemotherapy-induced nausea, vomiting, fatigue, and anemia. By enhancing the quality of life for patients and promoting treatment adherence, personalized supportive care not only addresses the challenges of cancer treatment but also enhances overall outcomes.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Cancer Supportive Care Drugs Market by Type

Market Overview
ESA (Erythropoiesis-Stimulating Agents)
G-CSFs (Granulocyte Colony-Stimulating Factors)
Antiemetics
Bisphosphonates
Opioids
NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
and Others

Global Cancer Supportive Care Drugs Market by Application

Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Stomach Cancer
and Others

Global Cancer Supportive Care Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amneal Pharmaceuticals LLC (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Helsinn Healthcare SA (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mundipharma International Limited (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kyowa Kirin Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments